J Clin Neurol.  2014 Apr;10(2):148-156. 10.3988/jcn.2014.10.2.148.

Validity of Korean Versions of the Multiple Sclerosis Impact Scale and the Multiple Sclerosis International Quality of Life Questionnaire

• Huh SY
• Joo J
• Kim SH
• Joung AR
• Park K
• Kim W
• Park MS
• Kim HJ

• KMID: 2287533
• DOI: http://doi.org/10.3988/jcn.2014.10.2.148

Abstract

BACKGROUND AND PURPOSE
Assessment of the health-related quality of life (HRQoL) is important in clinical evaluations of multiple sclerosis (MS) patients for quantifying the impact of illness and treatment on their daily lives. Although MS-specific HRQoL instruments have been used internationally, there are no data regarding HRQoL instruments specifically designed for patients with MS in Korea. The objective of this study was to determine the reliability and validity of the Korean Multiple Sclerosis Impact Scale (MSIS-29) and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire.
METHODS
Fifty-six patients with MS were recruited from June 2009 to February 2010 at the National Cancer Center in Korea. The original English versions of the MSIS-29 scale and the MusiQoL questionnaire were translated into Korean and evaluated for their acceptability, reliability, and validity.
RESULTS
The patients wereaged 36.5+/-8.6 years (mean+/-SD; range, 20-56 years). Their score on the Expanded Disability Status Scale was 2.0+/-1.9 (mean; range, 0-7.5), and their disease duration was 5.2+/-4.7 years (mean+/-SD; range, 1-24 years). The Korean versions of the MSIS-29 and MusiQoL questionnaires showed satisfactory psychometric properties, including construct validity (item-internal consistencies of 0.59-0.95 and 0.59-0.92, respectively; item-discriminant validities of 95-100% and 93.8-100%), internal consistency (Cronbach's alpha coefficients of 0.96-0.97 and 0.77-0.96), reliability (intraclass correlation coefficients of 0.78-0.90 and 0.50-0.93), unidimensionality (Loevinger scalability coefficients of 0.70-0.78 and 0.63-0.90), and acceptability. External validity testing indicated the presence of significant correlations between similar aspects of the two questionnaires.
CONCLUSIONS
The Korean translated versions of the MSIS-29 and MusiQoL questionnaires demonstrated reliability and validity for measuring HRQoL in Korean patients with MS.

Keyword

multiple sclerosis; health-related quality of life; MSIS-29; MusiQoL

MeSH Terms

Humans
Korea
Multiple Sclerosis*
Psychometrics
Quality of Life*
Reproducibility of Results
Surveys and Questionnaires

Reference

1. Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005; 4:556–566.

2. Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry. 2004; 49:157–163.

3. Miller DM, Kinkel RP. Health-related quality of life assessment in multiple sclerosis. Rev Neurol Dis. 2008; 5:56–64.

4. Solari A. Role of health-related quality of life measures in the routine care of people with multiple sclerosis. Health Qual Life Outcomes. 2005; 3:16.

5. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler. 2003; 9:63–72.

6. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001; 124(Pt 5):962–973.

7. Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008; 14:219–230.

8. Beiske AG, Baumstarck K, Nilsen RM, Simeoni MC. Validation of the multiple sclerosis international quality of life (MusiQoL) questionnaire in Norwegian patients. Acta Neurol Scand. 2012; 125:171–179.

9. Smedal T, Johansen HH, Myhr KM, Strand LI. Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29). Acta Neurol Scand. 2010; 122:244–251.

10. Triantafyllou N, Triantafillou A, Tsivgoulis G. Validity and Reliability of the Greek Version of the Multiple Sclerosis International Quality-of-Life Questionnaire. J Clin Neurol. 2009; 5:173–177.

11. Jamroz-Wiśniewska A, Stelmasiak Z, Bartosik-Psujek H. Validation analysis of the Polish version of the Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL). Neurol Neurochir Pol. 2011; 45:235–244.

12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33:1444–1452.

13. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46:1121–1123.

14. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999; 282:1737–1744.

15. Choi HS, Choi JH, Park KH, Joo KJ, Ga H, Ko HJ, et al. Standardization of the Korean version of Patient Health Questionnaire-9 as a screening instrument for major depressive disorder. J Korean Acad Fam Med. 2007; 28:114–119.

16. Kline P. An Easy Guide to Factor Analysis. New York: Routledge;1994.

17. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959; 56:81–105.

18. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995; 4:293–307.

19. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951; 16:297–334.

20. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86:420–428.

21. Wright BD, Stone MH. Best Test Design. Chicago: MESA Press;1979.

22. Gold SM, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler. 2001; 7:119–130.

23. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates;1988.

24. Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis. Acta Neurol Scand. 2001; 104:257–261.

25. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005; 231:29–34.

26. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler. 2011; 17:991–1001.

27. Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Henschel K, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000; 6:181–185.